MarketCap
Facebook
X
Telegram
Immunome Accounts Payables | IMNM
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Immunome
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.34 M | 14.2 M | 3.31 M | 2.4 M | 3.08 M | 1.19 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | 1.19 M | 4.58 M |
Quarterly Accounts Payables Immunome
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.34 M | 5.53 M | 14.2 M | 6.15 M | 4.66 M | 9.13 M | 14.2 M | 3.52 M | 7.05 M | 7.18 M | 3.31 M | 2.79 M | 3.7 M | 3.31 M | 2.4 M | 3.14 M | - | 3.89 M | 3.08 M | 3.28 M | 1.79 M | 2.96 M | 1.19 M | 1.19 M | 1.19 M | 1.19 M | 548 K | 548 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | 548 K | 4.24 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
3.62 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
2.08 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
1.88 M | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
2.51 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
261 K | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
1.11 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
663 K | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
4.43 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
2.4 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
1.41 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
1.45 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
4.16 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
1.28 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
14.9 M | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
3.59 B | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
1 M | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
139 M | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
432 M | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Exelixis
EXEL
|
29.6 M | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
11.3 M | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
715 M | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
116 M | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
INmune Bio
INMB
|
550 K | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
79.9 M | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
12 B | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
202 K | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
2.34 M | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
423 K | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
2.79 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
22.6 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
3.51 M | $ 0.39 | 0.15 % | $ 1.91 M | USA |
|
TFF Pharmaceuticals
TFFP
|
958 K | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.16 M | $ 1.63 | 1.87 % | $ 2.68 M |  Israel |
 |
Mirum Pharmaceuticals
MIRM
|
9.61 M | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.69 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
2.71 M | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
1.55 M | $ 1.09 | 6.37 % | $ 95 M | USA |